Relationships Between Financial Toxicity and Symptom Burden in Cancer Survivors: A Systematic Review. by Chan, Raymond Javan et al.
UC Irvine
UC Irvine Previously Published Works
Title
Relationships Between Financial Toxicity and Symptom Burden in Cancer Survivors: A 
Systematic Review.
Permalink
https://escholarship.org/uc/item/0b49j7fw
Journal
Journal of pain and symptom management, 57(3)
ISSN
0885-3924
Authors
Chan, Raymond Javan
Gordon, Louisa G
Tan, Chia Jie
et al.
Publication Date
2019-03-01
DOI
10.1016/j.jpainsymman.2018.12.003
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
646 Journal of Pain and Symptom Management Vol. 57 No. 3 March 2019Review ArticleRelationships Between Financial Toxicity and Symptom
Burden in Cancer Survivors: A Systematic Review
Raymond Javan Chan, PhD, Louisa G. Gordon, PhD, Chia Jie Tan, BPharm (Hons), Alexandre Chan, Pharm D,
Natalie K. Bradford, PhD, Patsy Yates, PhD, Oluwaseyifunmi Andi Agbejule, BRadTherapy, and
Christine Miaskowski, PhD
School of Nursing (R.J.C., L.G.G., N.K.B., P.Y., O.A.A., C.M.), Queensland University of Technology, Kelvin Grove, Queensland; Institute
of Health and Biomedical Innovation (R.J.C., N.K.B.), Queensland University of Technology, Kelvin Grove, Queensland; Princess
Alexandra Hospital (R.J.C.), Metro South Hospital and Health Services, Woolloongabba, Queensland; QIMR Berghofer Medical Research
Institute (L.G.G.), Herston, Queensland, Australia; Department of Pharmacy (C.J.T., A.C.), Faculty of Science, National University of
Singapore, Singapore; Department of Pharmacy (C.J.T., A.C.), National Cancer Centre, Singapore; and Department of Physiological Nursing
(C.M.), University of California, San Francisco, San Francisco, California, USAAbstract
Context. Financial toxicity (FT) is used to describe the financial distress/hardship associated with cancer and its treatment.
Objectives. The aim of this review was to explore the relationship between FT and symptom burden.
Method. A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines. We searched MEDLINE, EMBASE, and CINAHL (from January 2000 to January 2018) and accepted
quantitative, mixed-methods and qualitative studies. Data were extracted and appraised by two reviewers. Owing to significant
heterogeneity in the included studies, a narrative synthesis was performed.
Results. Nine studies involving 11,544 cancer survivors were included. Of these nine studies, eight were of high quality. The
relationships between FT and psychological symptoms and physical symptoms were examined in eight and three studies,
respectively. Six studies reported a positive relationship between FT and depression. Three studies found a positive association
between FT and anxiety. Limited evidence was found for an association between FT and stress, fear of recurrence, spiritual
suffering, pain, and overall symptom burden.
Conclusions. A relatively clear association exists between FT and psychological symptoms. Clinicians should regularly
screen for, assess, and manage emotional distress that may be attributed to FT. Although the causal pathway is not known,
future intervention studies aimed at minimizing or preventing FT should evaluate psychological symptoms as secondary
outcomes. Little is known about the relationships between FT and physical symptoms. Future research should overcome
methodological limitations by incorporating longitudinal data collection, use of mixed-methods approaches, and
homogeneity of samples. J Pain Symptom Manage 2019;57:646e660. Crown Copyright  2018 Published by Elsevier Inc. on behalf
of American Academy of Hospice and Palliative Medicine. All rights reserved.
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nances of patients and their family caregivers.5,6 The
term financial toxicity (FT) is used to describe the
financial distress or hardship associated with cancer
and its treatment.5,6
A recent systematic review reported that FT
occurred in 28% to 48% of cancer survivors using
monetary measures such as ‘‘percentage of household
income’’ (spent on medical services) and in 16% to
73% of cancer survivors using self-report measures
such as impact on everyday living expenses.4 In
another systematic review of 45 studies,6 12% to 62%
of cancer survivors reported being in debt due to their
treatment and 47% to 49% of survivors experienced
some form of financial distress.6 Common outcomes
associated with FT included reduced treatment
compliance, medication nonadherence, and treat-
ment refusal.4,6,7 Although several studies found that
higher financial burden was associated with reduc-
tions in health-related quality of life, especially with
emotional well-being,8e12 little is known about the
relationship between FT and symptom burden, espe-
cially the occurrence and severity of symptoms.13
Undoubtedly, the relationships between FT and
symptom burden are complex.13 Therefore, investiga-
tions that evaluate how FT and symptom burden may
interact with each other are warranted. Currently, it
is unclear whether the relationships between FT and
symptom burden are causal, bidirectional, or modi-
fying. For example, it is reasonable to postulate that
patients with a higher symptom burden (e.g., fatigue,
pain, cognitive dysfunction, depression, peripheral
neuropathy) may reduce hours at work or not be
able to return to work,14 which may exacerbate finan-
cial pressures. On the other hand, FT can contribute
to depression and anxiety,15 which may in turn influ-
ence physical symptoms such as sleep disturbance
and fatigue. Increased knowledge of the associations
between FT and symptom burden will inform the
development and testing of interventions to alleviate
symptom burden associated with FT.13 Therefore,
the primary aim of this review was to explore the rela-
tionships between FT and symptom burden in cancer
survivors.Methods
This systematic reviewwas prepared in accordancewith
thePreferredReporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines and was registered
prospectively in PROSPERO (ID 42016036924).
Identification of Studies and Inclusion Criteria
The following databases were searched: Medical
Literature Analysis and Retrieval System Online
(MEDLINE), Excerpta Medica Database (EMBASE),and Cumulative Index to Nursing and Allied Health
Literature (CINAHL) for articles published from
January 2000 to January 2018. In addition, we
searched the reference lists of any relevant studies
and reviews, as well as Google Scholar. The limits on
the years of publication were set due to the rapidly
evolving cancer treatment and care experiences of
cancer survivors. We defined ‘‘cancer survivors’’ as
people living with cancer from the time of diagnosis
until the end of life.16,17 The search strategies were
guided by the following four groups of search terms:
1) cancer, 2) patients, 3) cost, and 4) symptom
burden. Synonyms and related terms are detailed in
Table 1. For each of the terms in the four groups,
we used Boolean operators ‘‘OR’’ and between the
groups we used ‘‘AND.’’ We used medical subject
headings (MeSH) when available. To be included in
this current review, studies were required to meet
following prespecified criteria: published in English;
published or were in press in a peer reviewed journal;
and examined and reported the relationships between
FTand symptom burden in cancer survivors. Symptom
burden could be 1) assessed using the following di-
mensions: symptom occurrence, severity, frequency
and/or distress; 2) measured using valid and reliable
measures or investigator-constructed instruments;
and 3) reported by patients, proxy, or health care pro-
fessionals. Where symptom burden was reported as
part of a quality-of-life measure, symptom burden
had to be explicitly evaluated and reported. Defini-
tions and measures of FT used in this review were
informed by our previous systematic review.4 These
measures were categorized as 1) monetary: currency
values of out-of-pocket expenses and percentage of
out-of-pocket spending to income ratios; 2) objective:
question sets on tangible solutions to ease financial
burden such as to increase debt levels, borrow money
from family or friends, sell assets, withdraw money
from retirement or savings funds, file for bankruptcy;
and 3) subjective: question sets on perceptions of
cancer-related financial burden. No limitations were
placed on cancer stage or time since diagnosis. We
accepted quantitative, mixed-methods, and qualitative
research studies.
Study Screening and Data Extraction
The Endnote X8.2 referencing management soft-
ware (Clarivate Analytics, Philadelphia) was used for
the screening and inclusion of studies. One author
(O. A. A.) prescreened all search results (i.e., titles
and abstracts) for possible inclusion and selected arti-
cles for full-text assessment. Two authors (R. J. C. and
O. A. A.) independently assessed the full-text articles
for inclusion. All articles that met the prespecified in-
clusion criteria were included in this review. Data
extraction was conducted by one author (R. J. C.)
Table 1
Search Terms
1. Cancer: cancer care, oncology, treatment, management, p(a)ediatric, breast, prostate, colorectal, cervical, thyroid, brain, lung, lymphoma,
stomach, liver, MeSH cancer
2. Patients: patient, survivor, sufferer, family, MeSH patient care
3. Costs: cost, productivity loss, expense, treatment cost, out-of-pocket, economic burden, financial toxicity, financial hardship, financial
burden, financial effect, financial stress, co-payment, MeSH cost analysis
4. Symptom burden: symptom management, symptom burden, symptom occurrence, symptom distress, symptom severity, symptom
experience, symptom frequency, pain, fatigue, depression, anxiety, psychological stress
648 Vol. 57 No. 3 March 2019Chan et al.and checked by another author (C. M.). Data ex-
tracted included study methods, authors, publication
year, country, study design, setting, demographic char-
acteristics (i.e., age, income levels, educational levels,
health insurance, and employment status), clinical
characteristics (i.e., disease, disease stage, time since
diagnosis), outcome measures, and key findings.
Study Quality Assessment and Data Synthesis
Quality assessment was conducted independently by
two authors (R. J. C. and O. A. A.) using predefined
criteria adapted from Mols et al.’s standardized check-
list (see Supplementary Data 1).18,19 The checklist
included criteria for the quality indicators concerning
methodology, reporting, and interpretation of results.
Across the 12 items that were evaluated, if the study
met the quality indicator, it received one point. If
the study did not fulfill the specific criterion, did not
sufficiently describe whether the criterion was ful-
filled, or did not mention the criterion at all, a score
of zero was assigned. Studies that scored $75% of
the maximum attainable score (i.e., $9 points) were
considered ‘‘high quality.’’ Studies that scored be-
tween 50% and 75% were considered ‘‘moderate qual-
ity.’’ Studies scoring <50% were considered ‘‘low
quality’’ (i.e., #6 points).
We did not exclude studies based on study quality.
For the included studies, we expected significant het-
erogeneity in terms of methods and populations.
Although we initially planned to conduct a narrative
synthesis,20 because of the board range of cancer sur-
vivors who were evaluated in the included studies, we
summarized our study findings using two board
groups, namely cancer survivors with mixed stages of
disease or cancer type and those with advanced dis-
ease. For studies that provided measures of strength
of association, the strength of association for correla-
tion coefficients is described as weak if <0.3, moderate
if 0.3 to 0.5, strong if 0.5 to 0.7, and very strong if >0.7,
and for odds ratios as weak if < 2.5, moderate if 2.5 to
4.0, strong if 4.0 to 10.0, and very strong if >10.0.21
Results
The database searches resulted in 7162 titles. After
the addition of records identified through reference
lists and other sources (n ¼ 7) and the removal ofduplicates (n ¼ 1396), a total of 5773 were screened
and 24 full-text articles were retrieved for full assess-
ment. Of these 24 articles, a total of nine were
included. The PRISMA flowchart is shown in
Figure 1. The study characteristics and key findings
are reported in Table 2.Study Characteristics and Quality Assessment
Of the nine included studies, eight3,8,12,15,22e25
examined the relationships between FT and psycho-
logical symptoms. Three studies examined the rela-
tionships between FT and physical symptoms.15,22,26
Eight studies3,8,12,15,22e25 adopted a cross-sectional
design, and one longitudinal study26 collected data
over two time points. Six were conducted in the
U.S.,3,8,12,15,24,26 with the remainder in Australia,23
France,22 and Ireland.25 The sample sizes ranged
from 100 to 500,3,15,22,24 501 to 1000,25 1001 to
5,000,8,12,23 and >5000.26 All the studies used a quan-
titative observational design. Six studies8,12,23e26
included cancer survivors at various time points after
diagnosis, with the remainder including patients with
advanced cancer.3,15,22 Five studies recruited patients
from population-level registries,8,12,23,25,26 and four re-
cruited from local cancer centers.3,15,22,24 A range of
self-report measures of FT and symptom burden
were used across the nine studies. Only one study25
measured FT using monetary measures in addition
to subjective measures. However, this study only as-
sessed and reported the relationships between the sub-
jective measures of FT and symptom burden.25 These
measures are described in detail in Table 2. Most
studies were of high quality ($9).3,8,15,22e26 One study
was judged as low quality (#6),12 mainly due to lack of
use of validated measures, insufficient reporting of
cancer treatment types and informed consent, and a
relatively low response rate. Supplementary Data 1
summarizes the quality assessment criteria and results
for each study.Relationships Between Financial Toxicity and
Symptom Burden
Table 3 summarizes the findings on the relation-
ships between FT and symptom burden reported
across the nine studies. A number of studies reported
weak-to-moderate, positive relationships between FT
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Fig. 1. PRISMA flowchart.
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chological distress,3,22,24 stress, fear of recurrence,8,12
spiritual suffering,22 pain,26 and overall symptom
burden.22,26 In terms of the relationships between
FT and symptom burden, seven studies3,8,12,23e26 re-
ported results from their multivariable analyses con-
trolling for a number of demographic and clinical
characteristics, whereas the remaining two15,22 were
limited to univariate and bivariate analyses.
Cancer Survivors (Mixed Stage of Disease and Cancer Diag-
nosis). In an Irish study of 654 breast, prostate, and
lung cancer survivors (who were less than 6 months
after diagnosis), the multivariable analyses suggested
that the risks of depression and anxiety increased
almost threefold among those with increased cancer-
related financial stress and strain.25 In this study,
depression risk increased by threefold in survivors
who reported increased cancer-related financial stress
(OR ¼ 2.79, 95% CI 1.8-4.17) and increased
cancer-related financial strain (OR ¼ 3.56, 95% CI
2.23-5.67). Risk estimates were higher for those
survivors with severe or worse depression, and who
reported increased financial stress (OR ¼ 4.36, 95%CI 2.35-8.10), and increased financial strain
(OR ¼ 8.21, 95% CI 3.79-17.77).25 Similar associa-
tions were found for anxiety and distress.25 Similar
effect sizes were reported in the multivariable analysis
from another cross-sectional study of 1380 cancer
survivors (mixed cancer diagnoses) who were at
various time points after diagnosis.8 Specifically,
higher levels of depression, psychological distress,
and fear of recurrence were associated with a higher
number of financial problems (i.e., borrowed money
or declared bankruptcy, worried about paying large
medical bills, unable to cover costs of medical care
visits, other financial sacrifices).8 In a multivariable
analysis, compared with those who did not report
financial problems, the odds for depression and
being worried about cancer recurrence were 3.4 and
3.5 times more likely, respectively, for people with
three or more financial problems.8 In terms of worry
about cancer recurrence, in a U.S. study of 2108
cancer survivors, those who reported a higher level
of cancer-related financial problems were more likely
to worry ‘‘all the time’’ that the cancer would return
(43%) than those who did not worry about cancer
recurrence (28%; P < 0.001).12
Table 2
Summary of Characteristics and Findings From Included Studies
Author, Year, Country, Sample Size, Study
Purpose Patient Characteristics Measures, Analyses, and Key Findings Quality Scores, Strengths, and Weaknesses
Sharp, Carsin & Timmons, 2013
Ireland
N ¼ 654
Purpose: Investigate associations between
cancer-related financial stress and strain
and psychological outcomes among
cancer survivors
Setting: a population-based sample from the
National Cancer Registry Ireland (patients
less than six months after diagnosis)
Time frame: June to October 2008
Cancer type: breast (69.3%), prostate
(28.1%), and lung (2.6%)
Disease stage: NR
Treatment: Surgery (78.6%), CTX (43%),
XRT (65.6%), and HRT (39.8%)
Time since diagnosis (yrs): NR
Age range: 26e88 yrs
Male: 30.7%
Income level: Q1: lowest quartile (20.2%),
Q2 (21.9%), Q3 (23.6%), and Q4: highest
quartile (22.2%)
Education level: primary (19.2%), secondary
(51.2%), and tertiary (29.6%)
Health insurance at diagnosis: 66%
Health insurance at the time of study: NR
Employment status: employed (40.6%), self-
employed (12.3%), not working (24.5%),
and retired (22.6%)
Financial toxicity measures:
- Direct medical and nonmedical costs and
indirect costs as a result of cancer
- Objective Family Financial Stress Index
- Subjective financial straindassessed by one
question on how the respondents had felt
about the household’s financial situation
since their cancer diagnosis
- Cancer-related financial stressdassessed by
one question on the impact of the cancer
diagnosis on the household’s ability to
make ends meet
Symptom burden and other relevant
measures:
- DASS-21
Analysis:
- Logistic regression
Key findings:
- Depression risk increased by threefold in
participants reporting increased cancer-
related financial stress (OR ¼ 2.79, 95% CI
1.8-4.17) and increased cancer-related
financial strain (OR ¼ 3.56, 95% CI
2.23-5.67).
- Risk estimates were higher for severe or
worse depression, increased financial stress
(OR ¼ 4.36, 95 CI% 2.35-8.10), and
increased financial strain (OR ¼ 8.21, 95%
CI 3.79-17.77).
- Similar associations were reported for
anxiety and distress.
Quality score: 9
Strengths:
- Relatively large sample size (n ¼ 654)
Weaknesses:
- Participants had varying time since
diagnosis
- 97% were cancer types associated with
higher socioeconomic status (i.e., breast
and prostate)
Delgado-Guay et al., 2015
U.S.
N ¼ 149
Purpose: Examine the frequency of financial
distress and its correlates in patients with
advanced cancer
Setting: CCC and GPH
Time frame: NR
Cancer type: breast (26%), colorectal (24%),
lung (26%), and prostate (24%)
Disease stage: advanced stage
Treatment: CTX (77.2%), targeted therapy
(20.1%), and XRT (24.8%)
Time since diagnosis (yrs): NR
Median age: 60 yrs (95% CI 58.6-61.5)
Male: 50%
Income level: CCC patientsdmedian
monthly income of $3000 USD (IQR
$1400-7000); GPH patientsdmedian
monthly income of $940 USD (IQR:
$350-$1300)
Financial toxicity measures:
- Participants were asked to rate the impact
of financial distress using a ‘‘strongly agree’’
to strongly disagree’’ statement
- Four self-rated items on ‘‘subjective
financial burden,’’ ‘‘financial concerns,’’
‘‘financial difficulties,’’ ‘‘financial worries,’’
and using a numeric rating scale
(0 ¼ absent, 10 ¼ worst)
Symptom burden and other relevant
measures:
- ESAS, HADS, FACT-G, and MSPSS
Analysis:
- Pearson and Spearman correlation
Key findings:
Quality score: 9
Strengths:
- This study examined and compared
financial distress in two cohorts with
different income levels. This design
provides insights that FT does not only
affect people with lower income levels.
- This study measured symptom burden
including physical symptoms (ESAS)
Weaknesses:
- Use of nonvalidated scale to assess financial
toxicity
- Relatively small sample size, limited to
bivariate analyses
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Education level: college (32.6%), advanced
degree (9.6%), and high school or less
(57.8%)
Health insurance at diagnosis: NR
Health insurance at the time of study: NR
Employment status: NR
- Financial distress was reported as more
severe than physical distress, distress about
physical functioning, social/family distress,
and emotional distress by 45 (30%), 46
(31%), 64 (43%), and 55 (37%) of patients,
respectively (was significantly worse in
patients at GPH as than patients at the
CCC).
- Patients reported that financial distress was
affecting their well-being (0 ¼ not at all,
10 ¼ very much) with a median score of 5
(IQR: 1e8). FD correlated (Spearman
correlation) with FACT-G (r ¼ 0.23,
P ¼ 0.057), HADS-anxiety (r ¼ 0.27,
P ¼ 0.0014), ESAS-anxiety (r ¼ 0.2,
P ¼ 0.0151), and ESAS-depression
(r ¼ 0.18, P ¼ 0.0336).
- Financial distress was not significantly
correlated with other items on the ESAS
other than anxiety and depression
including pain, fatigue, nausea, drowsiness,
shortness of breath, appetite, sleep, feeling
of well-being, and spiritual pain
Barbaret et al., 2017
France
N ¼ 143
Purpose: Examine frequency and severity of
financial distress and its association with
quality of life and symptoms among
patients with advanced cancer
Setting: teaching hospital, CCC
Time frame: March 2013eJune 2014
Cancer type: lung (25%), breast (25%),
colorectal (25%), and prostate (25%)
Disease stage: metastatic (85%), relapse
(4%), locally advanced (8%), and other
(2%)
Treatment: surgery (52%), CTX (92%), XRT
(56%), and targeted (6%)
Time since diagnosis (days): had financial
distress: 1979 (4997), had no financial
distress: 1619 (1814)
Mean Age: 58 yrs
Male: 49%
Income level (annual): <$15,000 Euro
(38%), >$15,000 Euro (62%)
Education level: college (27%), completed
high school (15%), and did not complete
high school (59%)
Health insurance at diagnosis: NR
Health insurance at the time of study: 91%
Employment status: NR
Financial toxicity measures:
- Financial distress was assessed using a self-
rated numeric scale from 0 to 10
(0 ¼ absent, 10 ¼ worst). Patients were
considered to have FD if they rated 1 or
above on the 0e10 scale. High FD was
defined as rating 4 or abovedfour self-
rated items on ‘‘subjective financial
burden,’’ ‘‘financial concerns,’’ ‘‘financial
difficulties,’’ ‘‘financial worries,’’ and using
a numeric rating scale (0 ¼ absent,
10 ¼ worst).
Symptom burden and other relevant
measures:
- ESAS, HADS, FACT-G
Analysis:
- Student t-test, Chi-square (Mann-Whitney
or Fisher test), Pearson or Spearman
correlation ANOVA/Wilcoxon
Key findings:
- Patients with FD had higher HADS-D (8
versus 6 P ¼ 0.007) and HADS-A (9 versus
7, P ¼ 0.009) scores.
- FD was linked to increased total ESAS score
(P ¼ 0.005) and spiritual suffering
(P ¼ 0.045).
Quality score: 10
Strengths:
- This study measured symptom burden
including physical symptoms (ESAS).
Weaknesses:
- Use of nonvalidated scale to assess financial
toxicity
- Small sample size, limited to bivariate
analyses
de Souza et al., 2017
U.S.
N ¼ 233
Purpose: Examine the COST measure with
Setting: Cancer centers at the University of
Chicago Medicine and the NorthShore
University Health System.
Time frame: May 2013 to February 2015.
Financial toxicity measures:
- COST
Symptom burden and other relevant
measures:
Quality score: 9
Strengths:
- This study is the first to validate an
instrument to measure FT as a construct.
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Continued
Author, Year, Country, Sample Size, Study
Purpose Patient Characteristics Measures, Analyses, and Key Findings Quality Scores, Strengths, and Weaknesses
respect to its psychometric properties and
to evaluate if patient-reported financial
toxicity correlated with HRQOL.
Cancer type: NR
Disease Stage: Stage IV solid tumors
Treatment: NR
Time since diagnosis (y): <1 (39%), >1
(61%)
Median age (range): 59 (27e88)
Male: 41.6%
Income level: Median household income
(range) of poverty level ¼ 376.6%
(0e7964%)
Education level: < college (15.5%), some
college or technical training (37.3%),
completed college and above (47.2%)
Health insurance at diagnosis: NR
Health insurance at the time of study: Private
or employer-based (61.8%), Medicare
(31.3%), Medicaid (5.6%), COBRA
coverage (1.3%)
Employment status: Working (33.5%),
Unemployed (9%), Retired (32.6%), On
short-term/long-term disability (19.3%),
other (5.1%)
- Brief POMS, FACT-G, EORTC-C30
Analysis:
- Multivariable linear regression analyses
Key findings:
- FT (as measured by COST) was correlated
with income (correlation coefficient
[r] ¼ 0.28, P < 0.001), psychosocial distress
(r ¼ 0.26, P < 0.001), and HRQOL, as
measured by the FACT-G (r ¼ 0.42,
P < 0.001) and by the EORTC QOL
instruments (r ¼ 0.33, P < 0.001).
- Independent factors significantly associated
with FT were: race (P ¼ 0.4), employment
status (P < 0.001), income (P ¼ 0.003),
number of inpatient admissions (P ¼ 0.01),
and psychological distress (P ¼ 0.49).
Weaknesses:
- Sample was drawn from tertiary referral
centers where all participants had some
form of insurance coverage
- The sample was only limited to those with
ECOG performance status of <3
Hall et al., 2016
Australia
N ¼ 1414
Purpose: Explore outcomes of psychological
distress (including anxiety, depression,
and stress) in adult hematological cancer
survivors, with a specific focus on potential
differences between rural and urban
survivors.
Setting: five Australian state population-
based cancer registries
Cancer type: Hematological 100%: NHL
(55%e60%), leukemia (17%e18%),
myeloma (14%e16%), other lymphoma
(9%e11%)
Disease stage: NR
Treatment: CTX, XRT, BMT, and HRT
(21%e24%) (did not provide breakdown)
Time since diagnosis (months):
1e12 (6.7%e9.3%), 13e24 (13%),
25e36 (21%e24%), 37e60 (43%e51%),
>60 (2.7%e17%)
Age range: 15 to >70 yrs
Male: 57%
Income level: 41%e43%
Education level: high school and below
(49%e45%), vocational training (32%e
36%), university (19%e30%)
Health insurance at diagnosis: NR
Health insurance at the time of study: NR
Employment status: 41%e43%
Financial toxicity measures:
- Self-reported questionnaire (researcher
developed): financial difficulties as a result
of cancer (including a range of indicators
with varying impact)
Symptom burden and other relevant
measures:
- DASS-21
Analysis:
- Logistic regression
Key findings:
Factors associated with above normal levels
of anxiety: 40e49 yrs (vs. >70 yrs), single
(vs. partnered), less income, not taking
time off work.
Factors associated with above normal levels
of depression: 40e49 yrs (vs. >70 yrs),
lymphoma diagnoses (vs. myeloma),
currently receiving active treatment of
curative or palliative intent, other types of
care (vs. receiving follow-up appointment
only), had used up their savings due to
cancer, and did not have or were unsure of
their private health insurance.
Factors associated with above normal levels
of stress: 50e59 yrs (vs. >70 yrs), reported
Quality score: 11
Strengths:
- This study focused only on hematological
cancer.
Weaknesses:
- Use of nonvalidated measures of FT
- Relatively low response rate (35%), which
creates a potential for response bias
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difficulties in paying their bills due to
cancer, having used up their savings due to
cancer.
Kale and Carroll, 2016
U.S.
N ¼ 1380
Purpose: Determine the prevalence and
assess predictors of cancer-related
financial burden and examine the
association between financial burden and
HRQOL and psychological health
Setting: 2011 Medical Expenditure Panel
Survey (MEPS) data
Time frame: 2011
Cancer type: breast (17%), prostate (12%),
colorectal (4%), melanoma (6%), and
other (61%)
Disease stage: NR
Treatment: NR
Time since diagnosis (yrs): $5 (65%), <1
(6%), 1 to <3 (15%), 3e5 (14%)
Age: <65 (72%), $65 (28%)
Male: 44%
Income/poverty level: high (46%), medium
(29), low (12%), poor (13%) e (did not
define)
Education level: <high school (11%), high
school (28%), college (45%), and
>college (16%)
Health insurance at diagnosis: 92%
Health insurance at the time of study: 96%
Employment status: NR
Financial toxicity measures:
- The Cancer Self-Administered
Questionnaire (CSAQ):
1. You or anyone in family had to borrow
money or go into debt.
a. How much money was borrowed or
how much debt was incurred?
b. Have you or a family member ever
filed for bankruptcy?
2. Have you or a family member made any
other financial sacrifices?
3. Ever worried about paying large medical
bills?
4. Unable to cover cost of medical care
visits?
- Participants were judged to have a financial
burden if they answered ‘‘Yes’’ to one of the
above questions
- Authors also examined the number of
financial problems (range, 0e4) as a proxy
for the extent of financial burden: 1)
borrowed money, 2) declare bankruptcy, 3)
worried about paying large medical bills,
and 4) unable to cover cost of medical care
visits
Symptom burden and other relevant
measures:
- Depressed mood: Patient Health
Questionnaire-2
- Psychological distress: Index of Kessler
- Worries related to cancer recurrence, three-
question survey: 1) how often survivors
worry about cancer getting worse or
coming back, 2) how often they worry
about cancer recurrence affecting their
responsibilities at home or work, and 3)
what they believe about their changes of
cancer recurrence or the disease getting
worse within the next 10 years?
Analysis:
- Chi-square, Student t-tests, binary logistic
regression, and multivariable linear
regression
Key findings:
- Multivariable level: Compared with those
without financial burden, survivors with
financial burden (yes/no): 1) had
increased odds of depressed mood (odds
ratio, 1.95). [The odds for depressed mood
were 3.41 times higher for survivors
Quality score: 9
Strengths:
- Relatively large sample size (>1000)
Weaknesses:
- The data set did not include cancer stage
and treatment type and did not control for
these factors.
- Recall bias could be present because most
participants were diagnosed over five years
ago.
(Continued)
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Author, Year, Country, Sample Size, Study
Purpose Patient Characteristics Measures, Analyses, and Key Findings Quality Scores, Strengths, and Weaknesses
reporting $3 financial problems]; and 2)
were more likely to worry about cancer
recurrence (odds ratio, 3.54).
- Survivors reporting $3 financial problems
had 2.56 times higher odds of psychological
distress than those without.
Meeker et al., 2016
U.S.
N ¼ 120
Purpose: Assess and characterize the
relationships among financial distress,
emotional symptoms, and overall distress
in insured patients with cancer
Setting: Insured patients within a CCC
Time frame: September 2013 to April 2014
Cancer type: genitourinary (38%),
gastrointestinal (24%), gynecologic
(13%), sarcoma (8%), and other (17%)
Median age (range): 62 (22e87) yrs
Disease stage: NR
Treatment: Surgery (68%), CTX (67%),
XRT (39%), targeted therapy (16%), and
HRT (1%)
Time since diagnosis (yrs): <1 (37%), 1e3
(22%), 3e5 (17%), and >5 (25%)
Male: 48%
Income level: >100K (23%), 75e100K
(13%), 50Ke#75K (20%), 25Ke#50K
(20%), <25K (16%), and missing (8%)
Education level: <high school (7), high
school (33%), trade school/some college
(27%), degree (21%), advanced degree
(11%), and missing (1%)
Health insurance at diagnosis: 100%
Health insurance at the time of study: 100%
Employment status: retired (41%), used for
wages (26%), unable to walk (19%), out of
work (5%), other (6%), and missing (3%)
Financial toxicity measures:
- The InCharge Financial Distress/Financial
Well-being Scale
Symptom burden and other relevant
measures:
- Overall distress was measured using the
National Comprehensive Cancer Network
Distress Thermometer.
- Emotional distress was measured using the
self-reported six-item questionnaire (part
of the problems list).
Analysis:
- Structural equation modeling
Key findings:
- A 1-unit increase in the financial distress
scale (which indicates improved financial
well-being) leads to a 0.3-unit decrease in
the emotional distress scale (which
indicates less emotional distress)
(P ¼ 0.008).
- A 1-unit increase in the emotional distress
scale leads to a 0.58-unit increase in overall
distress (which indicates increased overall
distress) (P < 0.001).
- A 1-unit increase in the financial distress
scale (which indicates improved financial
well-being) leads to a 0.553-unit decrease in
overall distress (P < 0.001).
- After controlling for demographic
variables, the total effect was that a 1-unit
increase in the financial distress scale
(which indicates improved financial well-
being) leads to a 0.727-unit decrease in
overall distress.
- Conclusion: The total effect can be divided
into two routes: pathways A and B
(emotional distress mediates the
association between financial distress and
overall distress) and pathway C (financial
distress directly increases overall distress.
Quality score: 11
Strengths:
- This is the only one study that investigated
the mediating effects of emotional distress
between financial distress and overall
distress.
Weaknesses:
- The instrument used to measure both
overall and emotional distress is a screening
tool (i.e., the distress thermometer
problem checklist), which is not a validated
measure of emotional and overall distress.
- This study only included insured patients
receiving care at a CCC.
Lathan et al., 2016
U.S.
Setting: Cancer Care Outcomes Research
and Surveillance (CanCORS) Consortium.
Financial toxicity measures: Quality score: 9
Strengths:
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N ¼ 5343
Purpose: Measure the association between
patient financial strain and symptom
burden, and quality of life for patients
newly diagnosed with lung or colorectal
cancer
Time frame: cancer diagnosis between 2003
and 2005.
Cancer type: Colorectal (54%) and lung
(46%)
Treatment: NR
Male: 56%
Health insurance at diagnosis: NR
Health insurance at the time of study: 94%
Employment status: NR
Lung cancer (n ¼ 2434)
Disease stage: I (30%), II (9%), III (28%),
and IV (28%)
Time since diagnosis (months): baseline
(median): 4.2, follow-up interview
(median) 12.4
Age: <59 (27%), 60e69 (32%), 70e79
(30%), and $80 (10%)
Income level: <20K (34%), 20 to <40K
(31%), 40 to <50K (16%), and $60K
(18%)
Education level: <high school (21%), high
school (62%), and college degree or
higher (18%)
Colorectal cancer (n ¼ 2909)
Disease stage: I (30%), II (9%), III (28%),
and IV (28%)
Time since diagnosis (months): baseline
(median): 4.2, follow-up interview
(median) 12.4
Age: <59 (27%), 60e69 (32%), 70e79
(30%), and $80 (10%)
Income level: <20K (34%), 20 to <40K
(31%), 40 to <50K (16%), and $60K
(18%)
Education level: <high school (21%), high
school (62%), college degree or higher
(18%)
- Patients (or their surrogates) asked an
interview question, ‘‘If you lost all of your
current sources of income (for example,
your pay check, Social Security or pension,
public assistance) and had to live off of
your savings, how long could you continue
to live at your current address and standard
of living?’’ Response options were less than
one month, one to two months, three to six
months, 7e 12 months, more than
one year, and do not know
Symptom burden and other relevant
measures:
- BPI, EORTC-C30, and EQ5D
Analysis:
- Univariable and multivariable linear
regression and univariable and
multivariable ordinal logistic regression
(Spearman’s rank correlation coefficient
was used to examine the potential for
collinearity
Key findings:
- At four months after diagnosis: relative to
patients with more than 12 months of
financial reserves, those with limited
financial reserves reported significantly
increased pain (adjusted mean difference,
5.03 [95% CI 3.29 to 7.22] and 3.45 [95%
CI 1.25 to 5.66], respectively, for lung and
colorectal), greater symptom burden (5.25
[95% CI 3.29 to .22] and 5.31 [95% CI 3.58
to 7.04]), and poorer QOL (4.70 [95% CI
2.82 to 6.58] and 5.22 [95% CI 3.61 to
6.82]).
- At 12 months (since diagnosis), financial
strain was an independent predictor of
pain and depression (results not reported).
- Large sample size: >5000, this is the only
included study that measured financial
reserves
Weaknesses:
- N/A
Fenn et al., 2014
U.S.
N ¼ 2108
Purpose: Examine the relationship between
the financial problems caused by cancer
and quality of life
Setting: 2010 National Health Interview
(NHIS) Survey
Time frame: 2010
Cancer type: Multiple cancer type
Disease stage: NR
Treatment: NR
Time since diagnosis (yrs): NR
Age: NR
Male: NR
Income level: NR
Education level: NR
Health insurance at diagnosis: NR
Health insurance at the time of study: NR
Employment status: NR
Financial toxicity measures:
- The following question from the Cancer
Control Supplement, ‘‘To what degree has
cancer caused financial problems for you
and your family?’’ The question was
answered using a four-point scale ranging
from 0 ¼ not at all to 4 ¼ a lot.
Symptom burden and other relevant
measures:
- Worry of cancer recurrence: ‘‘what do you
think the chances that your cancer will
come back or get worse within the next
10 years?’’/and their worry regarding the
same ‘‘how often do you worry that your
cancer may come back or get worse?
Quality score: 6
Strengths:
- Relatively larger sample size >2000
- This study is the only longitudinal study
that provides insights about changes in
outcome measures over 12 months.
Weaknesses:
- This study did collect participant
characteristics, but did not report them.
(Continued)
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656 Vol. 57 No. 3 March 2019Chan et al.In an Australian study of 1414 hematological cancer
survivors, trouble meeting day-to-day expenses, difficulty
paying bills, stopped work, travel time to treatment, and
using home services in the last month were not associated
with anxiety and depression.23 However, not having
private health insurance was an independent predictor
of depression. Difficulty paying bills (OR: 1.94, 95%
CI 1.03-3.67) was an independent predictor of stress.
Using up savings was an independent predictor of
depression (OR: 1.79, 95% CI 1.10-2.92) and stress
(OR: 1.81, 95% CI 1.07-3.05).
To allow for a greater understanding of the direct
and indirect relationships between FT, emotional
distress, and overall distress, in a small U.S. study
(n ¼ 120) that examined the relationships between
these constructs in insured cancer survivors,24
financial distress was associated with overall distress
both directly (accounting for 76% of the effect) and
indirectly (accounting for 24% of the effect) via
mediation by emotional distress. Within this structural
equation model, a one-unit increase on the financial
distress scale (which indicates improved financial
well-being) led to a 0.3-unit decrease on the emotional
distress scale (which indicates less emotional distress;
P ¼ 0.008).24
Of the six studies that involved cancer survivors at
various time points after diagnosis, only one study
assessed physical symptoms.26 In a longitudinal study
of 5343 lung and colorectal survivors, those
individuals with greater financial strain (defined as
less financial reservesdthe length of time patients
could continue to live at their current address and
standard of living if they lost all their current sources
of income and had to live off their savings) had signif-
icantly higher levels of pain (adjusted mean difference
[MD] ¼ 5.03 [95% CI 3.29 to 7.22] and MD ¼ 3.45
[95% CI 1.25 to 5.66], respectively, for lung and
colorectal) and greater (overall) symptom burden
(MD ¼ 5.25 [95% CI 3.29 to .22] and MD ¼ 5.31
[95% CI 3.58 to 7.04]). At 12 months after diagnosis,
financial strain was an independent predictor of pain
and depression (results not reported).26
Cancer Survivors with Advanced Cancer
Three studies of patients with advanced cancer
(mixed cancer diagnoses) reported positive relation-
ships between FT and depression,15,22 anxiety,15,22
and psychological distress3 (all P < 0.05). In a French
study of 143 patients with advanced cancer, a
significant difference in spiritual suffering was found
between those with financial distress and those
without (P ¼ 0.045)22. In addition, patients with FT
had higher levels of depression (P ¼ 0.007), anxiety
(P ¼ 0.009), and total symptom burden (P ¼ 0.005).
In a research instrument validation study (n ¼ 233),3
higher psychological distress was independently
Table 3
Findings of Relationships Between Symptom Burden and Financial Toxicity (by Types of Measures)
Measures of FT
Physical Psychological and Spiritual Overall
Pain Dyspnea
Physical
Symptoms
Other Than
Pain Depression Anxiety Stress
Fear of
Recurrence
Spiritual
Suffering
Overall
Psychological
Distress
Overall
Symptom
Burden
1. Monetary measures
Sharp et al. 2013a NA NA NA NA NA NA NA NA NA NA
2. Objective measures
De Souza et al. 2017b NA NA NA NA NA NA NA NA þ (weak) NA
Hall et al. 2016c NA NA NA þ (weak) þ/d (weak) þ (weak) NA NA NA NA
Kale et al. 2016 NA NA NA þ (weak) NA NA þ (moderate) NA N NA
3. Subjective measures
Sharp et al. 2013e NA NA NA þ/f (moderate) þ/f (moderate) þ/f (moderate) NA NA NA NA
Delgado-Guay et al.
2015
N N N þ (weak)g þ (weak)g NA NA N NA NA
Barbaret et al. 2017h Measured, but
not reported
Measured, but
not reported
Measured, but
not reported
þ þ NA NA þ þ þ
De Souza et al. 2017i NA NA NA NA NA NA NA NA þ (weak) NA
Meeker et al. 2016h NA NA NA NA NA NA NA NA þ NA
Lathan et al. 2016j þ (weak) þ (weak) NA þ (weak) NA NA NA NA NA þ (weak)
Fenn et al. 2014h NA NA NA NA NA NA þ NA NA NA
‘‘þ’’ ¼ findings indicate a positive correlation; ‘‘’’ ¼ findings indicate a negative correlation; ‘‘N’’ ¼ findings indicate no correlation; ‘‘NA’’ ¼ did not assess; ESAS ¼ Edmonton Symptom Assessment System; HADS ¼
Hospital Anxiety and Depression Scale; FT ¼ financial toxicity.
aMonetary measures were used but only descriptive analysis was conducted.
bMeasure of FT used has both objective and subjective components.
cUsed multiple (7) measures to indicate FT.
dInconsistent direction of correlation for different indicators of FT: positive correlation with decreased income, but negative correlation with taking time off work.
eUsed two indicators of FT.
fFindings showed higher odds of anxiety, depression, and distress in both patients who have more and less concerns of their financial situation after being diagnosed with cancer, than those who report unchanged levels
of concern.
gBoth depression and anxiety were measured with two tools: ESAS and HADS.
hDid not report measures of strength of association.
iMeasure of FT used has both objective and subjective components.
jFindings for two separate disease cohorts (lung and colorectal cancer) were reported; however, findings were generally consistent.
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658 Vol. 57 No. 3 March 2019Chan et al.associated with worse self-perceived FT (P ¼ 0.003).3
Of the three studies that included patients with
advanced cancer, only one study (n ¼ 149) evaluated
psychological and physical symptoms.15 This study
reported positive correlations between FT (defined
as financial distress) and anxiety (r ¼ 0.2, P ¼ 0.015)
and depression (r ¼ 0.18, P ¼ 0.034). However, no
associations were found between FT and a range of
physical symptoms including pain, fatigue, nausea,
drowsiness, dyspnea, appetite, sleep, feeling of
well-being, and spiritual pain.15Discussion
Although the literature on FT has grown exponen-
tially over recent years,4 the relationships between
FT and symptom burden are not well understood. To
our knowledge, this systematic review is the first to
evaluate the literature that explored these
relationships. In this review, six studies found positive
relationships between increases in FT and higher
levels of psychological symptoms (i.e., depression
and anxiety). This finding has an immediate
implication for practice. Clinicians should regularly
screen for, assess, and manage emotional distress
related to FT when it occurs.13,27 The distress
thermometer and problem checklist28 could be
considered as a screening tool for distress potentially
attributed to FT. The checklist items relevant to FT
included those within the ‘‘practical problems’’
domain, which include childcare, housing, insur-
ance/financial, transportation, work/school, and
treatment decisions. Future intervention studies that
aim to minimize or prevent FT should evaluate
psychological symptoms as secondary outcomes. A
limited amount of emerging evidence suggests that
positive relationships exist between FT and
psychological (or existential) symptoms other than
depression and anxiety (e.g., fear of recurrence,12,24
spiritual suffering,22 stress).23 Measuring these
variables in future investigations of FT may
increase our understanding of the mechanisms that
underlie the associations between FT and symptom
burden.
In this review,only twoof thenine studies evaluatedand
reported physical symptoms.15,26 In the two studies that
examined the association between pain and FT, the
findings were inconsistent.15,26 Given the high
occurrence rates for fatigue, cognitive dysfunction,
pain, and sleep disturbance in cancer survivors,
additional research is warranted to examine the
relationships between these symptoms and FT. In
addition, it is important to consider symptoms that may
potentially affect work productivity (e.g., cognitive
dysfunction, fatigue) and in turn lead tofinancial distress.
In future studies, symptom inventories that are morecomprehensive innature and tailored for the appropriate
populations (e.g., patients undergoing active treatment,
long-term cancer survivors) should be considered.
Besides evaluating self-perceived symptoms using
patient-reported outcome tools, objective measures to
quantify symptomburden (e.g., neuropsychological tests,
biomarkers) should be included in future investigations.
Furthermore, it is important to determine if the
relationships between symptom burden and FT depend
on which measure of FT is used. The three types of FT
measures (i.e., monetary, objective, and subjective
measures) could capture different dimensions of
financial burden experienced by cancer survivors. The
findings from this review highlight that no study has
assessed the relationship between symptom burden and
FT using monetary measures. Although the use of
validated subjective FT measures (i.e., FACIT-COST)
has increased, well-recognized, monetary, and objective
measures are yet to be developed and validated. This
gap should be addressed in future studies.
The relationships between FT and symptom burden
are undoubtedly complex and warrant more in-depth
investigations. Below, we highlight a number of gaps
that should be addressed in future studies. Most of
the studies in this review involved a heterogeneous
sample of cancer survivors with various cancer
diagnoses, time points since diagnosis, and stage of
disease. These studies mainly focused on the
long-term impact of FT and symptom burden after
treatment ends. Because FT may occur at the time of
or even before diagnosis,29 the studies cited in this
review do not provide a comprehensive understanding
of when FT occurs and how FT is associated with and/
or interacts with symptom burden at an early stage of
the cancer trajectory. The lack of longitudinal studies
with multiple measures of both FT and symptoms limit
our ability to develop predictive models. Future
research should use a longitudinal design and
examine which phenotypic and symptom characteris-
tics are associated with a worse FT trajectory and the
direction of these relationships. As financial distress
can emerge from causes unrelated to cancer, the use
of control groups is important to determine the
proportion of financial distress attributable to cancer,
especially since a significant portion of FT outcomes
are subjectively reported by patients. Interestingly, we
were unable to locate any mixed-methods or
qualitative studies in our search. A mixed-methods
approach will likely offer insights into these complex
relationships. Qualitative approaches will allow
investigators to explore and understand aspects of
FT not adequately described by outcomes defined in
quantitative studies. This approach will provide a
more comprehensive picture of FT and can further
assess if FT outcomes evaluated in existing studies
are sufficiently sensitive to describe the financial
Supplementary data
Supplementary data related to this article can be
found at https://doi.org/10.1016/j.jpainsymman.
2018.12.003.
Vol. 57 No. 3 March 2019 659Financial Toxicity and Symptom Burdendistress experienced by cancer survivors. In addition
to investigating the relationships between FT and indi-
vidual symptoms, there might be value in understand-
ing the relationships between FT and symptom
burden (as a collective measure).22,26
Several limitations warrant consideration. First, we
did not do an exhaustive search including the ‘‘gray
literature’’ and databases that are suitable for
publications in South America and China. In addition
to key medical literature databases (i.e., MEDLINE,
CINAHL, and EMBASE), we hand-searched the
reference lists of all relevant articles and reviewers, as
well as Google Scholar. It is unlikely that any English
articles were missed. Second, the included studies
involved samples from high-income, developed
countries including the U.S., Australia, France, and
Ireland. It is likely that people in different health
systems have different experiences of FT. With the
limited studies conducted with high variations in the
study samples across a small number of countries, it
makes comparisons across multiple countries or health
systems impossible. Therefore, the findings from this
review cannot be generalized to other parts of the
world. Third, publication bias could potentially exist
where negative findings were not published at all or
were not published in the English language. However,
given the small number of included studies, we were
not able to assess publication bias. Despite these
limitations, this review is thefirst to explore the relation-
ships between FT and symptom burden and provided
recommendations for future research.Conclusions
Based on the findings from this review, relatively
clear evidence supports an association between FT
and psychological symptoms. Clinicians should
regularly screen for, assess, and manage emotional
distress that is attributable to FT. Although the causal
pathway is not yet clear, future intervention studies
aimed at minimizing or preventing FT may
incorporate psychological symptoms as secondary
outcomes. Little is known about the relationships
between FT and physical symptoms. Future research
should overcome the methodological limitations of
the current literature including the lack of longitudi-
nal data collection, use of mixed-methods approaches,
inclusion of validated monetary, subjective, and
objective FT measures, and homogeneity of samples.
This review did not evaluate workability and work pro-
ductivity, which is closely related to FT, an evaluation
of the association between symptom burden, financial
hardship, and workability and productivity outcomes
might provide insights to support the development
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id the study explain how the patient sample was
selected?
1 1 1 1 1 1 1 1 1
as the inclusion/exclusion criteria clearly
formulated?
1 1 1 1 1 1 1 1 1
as the sociodemographic and medical data
described (age, race, employment status,
educational status, tumor stage, diagnosis etc.) in
the study?
1 1 1 1 1 1 1 1 1
the type of (cancer) treatment described? 1 1 1 0 1 0 1 0 0
e the results of study compared between two or
more groups (healthy population, groups with
different cancer treatment or age, comparison
with time at diagnosis etc.)?
0 1 0 0 1 0 0 0 0
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of time since diagnosis and treatment given?
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ere the participation and response rates of the
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as information about patient/disease
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as a standardized or valid quality of life/symptom
measure (i.e., questionnaire, scale) used?
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e mean, median, standard deviations, or
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outcome measures?
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as an attempt made to find a set of determinants
with the highest prognostic value?
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id the patient sign an informed consent form
before study participation?
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te. 1 ¼ yes; 0 ¼ no; each yes score is assessed 1 point: studies with $10 points ¼ high quality, studies with 7 to 9 points ¼ moderate quality, and studies with #6 points ¼ low quality.
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